Lantheus (LNTH) to Release Earnings on Thursday

Lantheus (NASDAQ:LNTH) will likely be announcing its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of $1.17 per share and revenue of $367.0310 million for the quarter. Interested persons may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, February 26, 2026 at 8:00 AM ET.

Lantheus Stock Performance

LNTH stock opened at $73.61 on Wednesday. The firm has a 50 day moving average of $67.55 and a two-hundred day moving average of $59.79. Lantheus has a 12 month low of $47.25 and a 12 month high of $111.29. The company has a market capitalization of $4.88 billion, a price-to-earnings ratio of 30.93 and a beta of -0.08. The company has a quick ratio of 2.49, a current ratio of 2.67 and a debt-to-equity ratio of 0.51.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the stock. Weiss Ratings upgraded shares of Lantheus from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Tuesday, January 6th. Citizens Jmp raised their price target on shares of Lantheus from $73.00 to $78.00 and gave the company a “market outperform” rating in a report on Tuesday. Truist Financial boosted their price objective on shares of Lantheus from $80.00 to $82.00 and gave the stock a “buy” rating in a research report on Thursday, December 18th. Citigroup reiterated an “outperform” rating on shares of Lantheus in a research report on Tuesday. Finally, Mizuho boosted their price target on shares of Lantheus from $60.00 to $72.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 17th. Six equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $78.83.

Hedge Funds Weigh In On Lantheus

Large investors have recently added to or reduced their stakes in the company. Farallon Capital Management LLC lifted its holdings in Lantheus by 56.1% during the 4th quarter. Farallon Capital Management LLC now owns 5,427,479 shares of the medical equipment provider’s stock valued at $361,199,000 after purchasing an additional 1,950,252 shares during the last quarter. Freestone Grove Partners LP increased its holdings in shares of Lantheus by 4,114.8% in the fourth quarter. Freestone Grove Partners LP now owns 608,526 shares of the medical equipment provider’s stock valued at $40,497,000 after purchasing an additional 594,088 shares during the last quarter. Summit Street Capital Management LLC bought a new position in shares of Lantheus in the fourth quarter valued at about $26,997,000. AQR Capital Management LLC lifted its stake in shares of Lantheus by 368.0% during the 4th quarter. AQR Capital Management LLC now owns 403,622 shares of the medical equipment provider’s stock worth $26,861,000 after buying an additional 317,384 shares during the last quarter. Finally, Carmignac Gestion lifted its stake in shares of Lantheus by 39.0% during the 4th quarter. Carmignac Gestion now owns 1,122,000 shares of the medical equipment provider’s stock worth $74,669,000 after buying an additional 314,591 shares during the last quarter. Institutional investors own 99.06% of the company’s stock.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.